Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Rating of “Moderate Buy” by Analysts

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have been given an average rating of “Moderate Buy” by the five analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $20.00.

Several brokerages recently issued reports on ABEO. Weiss Ratings reiterated a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, October 13th. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th.

Abeona Therapeutics Trading Down 5.5%

ABEO opened at $4.83 on Friday. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. Abeona Therapeutics has a 52 week low of $3.93 and a 52 week high of $7.54. The stock has a market cap of $261.74 million, a PE ratio of 3.93 and a beta of 1.12. The business has a 50 day moving average of $5.12 and a 200-day moving average of $5.62.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. Equities research analysts predict that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Abeona Therapeutics

In other news, Director Mark Alvino sold 15,000 shares of Abeona Therapeutics stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $4.74, for a total value of $71,100.00. Following the completion of the transaction, the director owned 62,252 shares of the company’s stock, valued at $295,074.48. The trade was a 19.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brendan M. O’malley sold 13,578 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total transaction of $72,370.74. Following the completion of the transaction, the senior vice president owned 451,134 shares in the company, valued at approximately $2,404,544.22. The trade was a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 168,186 shares of company stock valued at $885,227 in the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new position in shares of Abeona Therapeutics in the second quarter worth approximately $25,000. Legal & General Group Plc purchased a new position in Abeona Therapeutics in the 2nd quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new position in Abeona Therapeutics in the 3rd quarter valued at approximately $37,000. SG Americas Securities LLC purchased a new stake in Abeona Therapeutics during the 4th quarter valued at $57,000. Finally, Legato Capital Management LLC purchased a new stake in Abeona Therapeutics during the 3rd quarter valued at $57,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.